Site-specific glycosylation patterns on circulating TREM2 ectodomain fragments distinguish senescent from activated microglia states in neurodegeneration. Unlike proteolytic cleavage ratios, this approach leverages differential glycosyltransferase activity (ST6GAL1, MGAT5) that occurs during microglial senescence transitions. Senescent microglia exhibit altered N-linked glycan branching and sialylation on TREM2 before ectodomain shedding, creating distinct glycoform signatures detectable in plas
Site-specific glycosylation patterns on circulating TREM2 ectodomain fragments reflect the metabolic state and activation history of CNS microglia, serving as predictive biomarkers for anti-neuroinflammatory therapeutic responses. The hypothesis posits that microglial priming states differentially regulate glycosyltransferase expression (particularly ST6GAL1, MGAT5, and FUT8), leading to distinct N-linked and O-linked glycan signatures on TREM2 ectodomains shed into circulation. Unlike CSF fragm
Convergent vs Divergent Predictions
This summary checks where the selected hypotheses point toward the same target or mechanism, and where they pull in opposite directions.
MGAT5 recurs across 2 selected hypotheses with aligned directionality in neuroinflammation, senescence.
ST6GAL1 recurs across 2 selected hypotheses with aligned directionality in neuroinflammation, senescence.
TREM2 recurs across 2 selected hypotheses with aligned directionality in neuroinflammation, senescence.
Divergent signals
No direct polarity conflicts detected among the selected hypotheses.
Verdict Summary
7/11
dimensions won
Plasma TREM2 Ectodomain Glycosylation Pa
8/11
dimensions won
Plasma TREM2 Ectodomain Glycosylation Pa
Radar Chart — 10 Dimensions
Score Comparison Bars
Mechanistic
0.70
0.70
Evidence
0.00
0.27
Novelty
0.00
0.00
Feasibility
0.00
0.00
Impact
0.00
0.00
Druggability
0.88
0.88
Safety
0.85
0.85
Competition
0.70
0.70
Data
0.50
0.50
Reproducible
0.52
0.52
KG Connect
0.50
0.50
Score Breakdown
Dimension
Plasma TREM2 Ectodomain Glycos
Plasma TREM2 Ectodomain Glycos
Mechanistic
0.700
0.700
Evidence
0.000
0.270
Novelty
0.000
0.000
Feasibility
0.000
0.000
Impact
0.000
0.000
Druggability
0.880
0.880
Safety
0.850
0.850
Competition
0.700
0.700
Data
0.500
0.500
Reproducible
0.520
0.520
KG Connect
0.500
0.500
Evidence
Plasma TREM2 Ectodomain Glycosylation Patterns as Microglial
No evidence citations yet
Plasma TREM2 Ectodomain Glycosylation Pattern as Therapeutic
No evidence citations yet
Debate Excerpts
Plasma TREM2 Ectodomain Glycosylation Patterns as
4 rounds · quality: 0.75
Theorist
# Biomarker Hypotheses for Detecting Microglial Priming States
---
## Hypothesis 1: TSPO PET Kinetic Modeling for Priming State Discrimination
**Title:** Distinguishing primed from dystrophic micro...
Skeptic
# Critical Evaluation of Microglial Priming Biomarker Hypotheses
## Hypothesis 1: TSPO PET Kinetic Modeling
### Weak Links
**Specificity Crisis.** TSPO is expressed on microglia, astrocytes, endoth...
Domain Expert
# Feasibility Assessment: Microglial Priming Biomarkers
## Executive Summary
The debate identified a fundamental translational gap: even validated microglial targets remain therapeutically inaccessi...
Plasma TREM2 Ectodomain Glycosylation Pattern as T
4 rounds · quality: 0.75
Theorist
# Biomarker Hypotheses for Detecting Microglial Priming States
---
## Hypothesis 1: TSPO PET Kinetic Modeling for Priming State Discrimination
**Title:** Distinguishing primed from dystrophic micro...
Skeptic
# Critical Evaluation of Microglial Priming Biomarker Hypotheses
## Hypothesis 1: TSPO PET Kinetic Modeling
### Weak Links
**Specificity Crisis.** TSPO is expressed on microglia, astrocytes, endoth...
Domain Expert
# Feasibility Assessment: Microglial Priming Biomarkers
## Executive Summary
The debate identified a fundamental translational gap: even validated microglial targets remain therapeutically inaccessi...